Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.66 |
| ▸ | MAG | P20916 | 8/20 | 0.61 |
| ▸ | SELL | P14151 | 1/20 | 0.52 |
| ▸ | SELP | P16109 | 1/20 | 0.52 |
| ▸ | SELE | P16581 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454804 | 0.96 | SIGLEC7 (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL21570084 | 0.95 | SIGLEC7 (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29364999 | 0.95 | SIGLEC7 (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL28957980 | 0.95 | SIGLEC7 (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL28957979 | 0.95 | SIGLEC7 (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL21570085 | 0.95 | SIGLEC7 (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL23857822 | 0.93 | MAG (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29361397 | 0.93 | MAG (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29809799 | 0.92 | SIGLEC7 (0.63) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL29790139 | 0.92 | SIGLEC7 (0.63) | SIGLEC7MAGSELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062726-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | DSM IP ASSETS BV (NL) | 2026-03-05 | — | — | US | claimed |
| EP-4662224-A1 | PRODUCTION OF A SACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF LACTOBIONIC ACID | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | claimed |
| EP-4577061-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | DSM IP Assets B.V. (NL) | 2025-07-02 | — | — | EP | claimed |
| CN-120018780-A | Hybrid process for producing complex HMO | 帝斯曼知识产权资产管理有限公司 | 2025-05-16 | — | — | CN | claimed |
| WO-2024165525-A1 | PRODUCTION OF A SACCHARIDE, LACTOBIONIC ACID AND/OR GLYCOSYLATED FORMS OF LACTOBIONIC ACID | INBIOSE N.V. (BE) | 2024-08-15 | — | — | WO | claimed |
| WO-2024165524-A1 | PRODUCTION OF A SACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF LACTOBIONIC ACID | INBIOSE N.V. (BE) | 2024-08-15 | — | — | WO | claimed |
| WO-2024042235-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | DSM IP ASSETS B.V. (NL) | 2024-02-29 | — | — | WO | claimed |
| EP-3407893-B1 | HUMAN MILK OLIGOSACCHARIDES AGAINST LATER IN LIFE EXCESSIVE FAT MASS ACCUMULATION AND RELATED HEALTH DISORDERS | NESTLE SA (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20260062726-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | DSM IP ASSETS BV (NL) | 2026-03-05 | — | — | US | disclosed |
| US-20260015637-A1 | SIGMA FACTOR MODIFICATIONS FOR BIOSYNTHETIC PRODUCTION | DSM IP ASSETS BV (NL) | 2026-01-15 | — | — | US | disclosed |
| EP-4652175-A1 | PURIFICATION OF A SACCHARIDE FROM A FERMENTATION BROTH | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025206361-A1 | GENETICALLY MODIFIED MICROORGANISM AND METHOD FOR PRODUCING SUGAR | キリンホールディングス株式会社 | 2025-10-02 | — | — | WO | disclosed |
| WO-2025205666-A1 | PROTEIN USEFUL FOR PRODUCTION OF HUMAN MILK OLIGOSACCHARIDE DSLNT | 国立大学法人東海国立大学機構 | 2025-10-02 | — | — | WO | disclosed |
| EP-3452051-B1 | COMPOSITION COMPRISING HMOS FOR USE IN THE TREATMENT OF MAST CELL MEDIATED VISCERAL HYPERSENSITIVITY AND/OR PAIN | GLYCOM AS (DK) | 2022-06-01 | — | — | EP | disclosed |
| US-11324765-B2 | Inhibiting inflammation with milk oligosaccharides | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220133759-A1 | SYNTHETIC COMPOSITION | GLYCOM A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| US-20220133758-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220119437-A1 | SYNTHESIS OF OLIGOSACCHARIDES | GLYCOM AS (DK) | 2022-04-21 | — | — | US | disclosed |
| EP-3980542-A1 | OPTIMAL CHROMOSOMAL INSERTION LOCI | Inbiose N.V. (BE) | 2022-04-13 | — | — | EP | disclosed |
| US-20220040212-A1 | ORAL REHYDRATION COMPOSITION WITH OLIGOSACCHARIDES | ABBOTT LABORATORIES (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133759-A1 | SYNTHETIC COMPOSITION | LCT, HTR6, TPH2 | SIGLEC7 990/4885MAG 304/4885SELL 1332/4885 |
| US-11324765-B2 | Inhibiting inflammation with milk oligosaccharides | FUT5, FUT6, ST3GAL3 | SIGLEC7 10/4885MAG 1011/4885SELL 132/4885 |
| US-20260062726-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | FUCA1, GMDS, MANBA | SIGLEC7 474/4885MAG 2423/4885SELL 2472/4885 |
| US-20220133758-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS | FUT6, FUCA2, FUCA1 | SIGLEC7 86/4885MAG 1345/4885SELL 311/4885 |
| US-20220119437-A1 | SYNTHESIS OF OLIGOSACCHARIDES | MGAM, LCT, LPO | SIGLEC7 261/4885MAG 911/4885SELL 1886/4885 |
| US-20260015637-A1 | SIGMA FACTOR MODIFICATIONS FOR BIOSYNTHETIC PRODUCTION | RNGTT, PURB, SLTM | SIGLEC7 186/4885MAG 2094/4885SELL 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.